Preclinical Stage Program


MEG100 is an allogeneic megakaryocyte product differentiated from hematopoietic stem cells (HSCs) isolated from umbilical cord blood.

Megakaryocytes naturally form platelets in the body and thus offer therapeutic potential for the treatment of the most common platelet deficiencies such as our target indication, thrombocytopenia. The success of platelet therapy is hampered by risks to product supply and to patient safety due to use of a large network of volunteer donors necessitated by the short shelf life of platelets.

MEG100 aims to overcome these limitations by offering patients a new treatment option where platelets are produced naturally within their own body by infused megakaryocytes, rather than repeat transfusions of platelets.


Platelet Therapy

Platelet transfusion has been in medical practice for 70 years also and is considered among the most effective and safest medicines. Millions of platelet units are transfused annually in the U.S. The majority are used for patients with blood cancers or other hematological disorders to prevent bleeding during chemotherapy or stem cell transplants. However, platelets have a limited shelf-life of 5 days, which necessitates developing a complex infrastructure to collect and deliver this type of therapy. MEG100 aims to overcome the supply and logistical limitations of platelet transfusions.


Our cell differentiation technology uses a scalable cell culture method to produce a cryopreservable megakaryocyte therapeutic product that can be stored long-term. This promises to eliminate the supply chain, storage, and safety limitations associated with traditional platelet products sourced from volunteer donors. Unlike newer approaches in development that aim to manufacture platelets using specialized bioreactors. MEG100 does not require this complexity since megakaryocytes produce platelets naturally within the body. MEG100 does not require this complexity since megakaryocytes produce platelets naturally within the body.

Patel A, Clementelli CM, Jarocha D, Mosoyan G, Else C, Kintali M, Fong H, Tong J, Gordon R, Gillespie V, Keyzner A, Poncz M, Hoffman R, Iancu-Rubin C. Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in miceTransfusion. 2019 Dec.

MEG100 Advantages


Thrombocytopenia is a medical condition that occurs when a patient does not have enough platelets in his or her blood, resulting in a high risk for bleeding. Thrombocytopenia can be inherited or can be caused as a result of several conditions or medications. Circulating platelets can be reduced by decreased platelet production, increased destruction, or being trapped in the spleen. Sometimes a drug confuses the immune system and makes it destroy platelets. Examples include heparin, quinine, sulfa-containing antibiotics, and anticonvulsants.